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Background: The addition of domiciliary non-invasive ventilation (NIV) to standard therapy in
chronic obstructive pulmonary disease (COPD) patients with compensated ventilatory failure
(CVF) is reported to have beneficial effects. Compliance with NIV is an important factor. Vol-
ume assured NIV (va-NIV) may improve compliance and ventilation during sleep by automati-
cally titrating ventilatory pressures.
Methods: A prospective single centre, randomised, parallel group trial comparing va-NIV and
pressure preset NIV (pp-NIV) in COPD patients with CVF naı¨ve to domiciliary NIV was performed
(ISCRTN91892415). The primary outcomes were arterial blood gases, mean overnight oximetry
(mSpO2) and compliance after three months. Secondary outcomes included pulmonary func-
tion, exercise capacity and health-related quality of life assessment.
Results: Forty patients were randomised in a 1:1 ratio. The va-NIV median target minute venti-
lation was 8.4 L/min and pp-NIV median inspiratory pressure was 28 cmH2O. There were no sig-
nificant differences between groups in primary or secondary outcomes after three months.
Mean (SD) PaO2 8.7 (1.7) versus 7.9 (1.7) kPa (p Z 0.19), PaCO2 6.7 (0.5) versus 7.3 (1.1)
kPa (p Z 0.1), mSpO2 89.7 (4.2) versus 89.8 (3.9) % (p Z 0.95), compliance 5.0 (3.1) versus
4.7 (3.2) hours (pZ 0.8) in va-NIV versus pp-NIV respectively. Patients allocated va-NIV spent
fewer days in hospital initiating therapy 3.3 (1.6) versus 5.2 (2.8) (p Z 0.02). Both groups
showed significant improvements in PaCO2 and mSpO2 after three months treatment.
Conclusions: Domiciliary va-NIV and pp-NIV have similar effects on physiological outcomes in
COPD patients with CVF and both are well tolerated.
ª 2014 Elsevier Ltd. All rights reserved.1480 830541; fax: þ44 01480 364558.
apworth.nhs.uk (N.S.Oscroft).
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Va-NIV versus pp-NIV for ventilatory failure in COPD 1509IntroductionRandomised controlled trials have shown significant im-
provements in health-related quality of life, exercise ca-
pacity, gas exchange and adjusted survival with the addition
of domiciliary non-invasive ventilation (NIV) to standard
therapy in chronic obstructive pulmonary disease (COPD)
patients with ventilatory failure [1,2]. Compliance with NIV
has been demonstrated to be an important factorwith longer
hours of use associated with improved survival [1]. To
ameliorate the hypoventilation during sleep associated with
severe COPD [3] NIV is usually worn overnight. Historically
NIV has been titrated to patient comfort [4] in an attempt to
improve compliance, and as a consequence relatively low
ventilatory pressures have been used. However, it is likely
that higher pressures are required to adequately control
hypoventilation [5] and reduce diurnal hypercapnia [6]. The
use of high pressures increases mask leak [7] and can delay
sleep onset. These factors may reduce compliance.
Volume assuredNIV (va-NIV) is amode of positive pressure
NIV that automatically adjusts inspiratory pressure support,
within a predetermined range, to maintain minute ventila-
tion and has been shown to have good leak compensation
ability [8]. It offers an alternative to standard pressure pre-
set (pp-NIV) modes and may improve compliance. Theoreti-
cally va-NIV may improve patient comfort by minimising
pressure support when patient effort is maintained during
wakefulness and increase pressure support as required dur-
ing sleep improving ventilation [9] and sleep quality [10]. In
addition va-NIV may alleviate the need for complex moni-
toring of patients overnight and manual titration of venti-
lator parameters when starting therapy.
The purpose of this study was to compare over a three
month period the effects of initiating va-NIV and pp-NIV in
COPD patients with compensated ventilatory failure (CVF)
naı¨ve to domiciliary NIV. The primary outcomes were
selected to reflect the clinically important outcomes of
efficacy of ventilation and compliance. Outcomes assessed
included diurnal arterial blood gases, compliance, param-
eters of nocturnal ventilation, lung function, exercise ca-
pacity and health-related quality of life.
Methods
A prospective single centre, randomised, parallel group
trial comparing pp-NIV and va-NIV in COPD patients with
compensated ventilatory failure was performed. Written
consent was obtained from all participants. A computer
based randomisation sequence produced by the trial stat-
istician determined treatment allocation. Randomisation
was performed by the hospital’s Research and Development
Department, independently of the research team, using
sealed opaque envelopes. The trial had the approval of the
Huntingdon Research Ethics Committee and was registered
in advance on a public database (ISCRTN91892415).
Population
Subjects were recruited from among patients referred to
the Respiratory Support and Sleep Centre (RSSC), Papworth
Hospital NHS Foundation Trust. The RSSC is a specialist unitthat accepts referrals from other respiratory physicians for
consideration of domiciliary NIV, electively or following
acute exacerbation when ventilatory failure persists. Study
inclusion criteria were: diagnosis of COPD with a forced
expiratory volume in 1 s (FEV1) <50% predicted, FEV1/
forced vital capacity (FVC) ratio < 70% and total lung ca-
pacity (TLC) > 80% predicted; smoking history of greater
than 20 pack years; ventilatory failure with a daytime
PaCO2 > 7 kPa with a pH > 7.35 or nocturnal trans-
cutaneous PaCO2 > 9 kPa. Exclusion criteria were: age
greater than 80 years; other significant respiratory disease
e.g. bronchiectasis; clinically significant left ventricular
dysfunction; body mass index >40 kg/m2; significant
obstructive sleep apnoea defined as an apnoea hypopnoea
index (AHI) of >10/hr; intubation or tracheostomy within
three months.
Intervention
Pp-NIV (NIPPY 3, B and D Electromedical, Stratford, UK) or
va-NIV (intelligent volume assured pressure support
(iVAPS), ResMed, Bella Vista, Australia) were used in a
spontaneous/timed setting. A range of interfaces including
nasal and full face masks were used and humidification
added as required. Standard single circuits (expiratory port
via nasal/full face mask) with identical 2 m hosing and fil-
ters were used with both ventilators. Once pp-NIV and va-
NIV were optimised oxygen therapy was added if patients
met the PaO2 criteria for long term oxygen therapy. [11]
Pp-NIV was titrated during attended respiratory moni-
toring including continuous transcutaneous PaCO2 (PtcCO2)
measurement and pulse oximetry by experienced nurses.
For pp-NIV the expiratory pressure was set at 5cmH20 and
the inspiratory pressures were increased and inspiratory
time and back-up rate adjusted to optimise ventilation with
the aim of reducing PtcCO2. These values were documented
prior to discharge and not subsequently altered.
The optimum setting of target minute ventilation (TgMV)
in severe COPD for domiciliary NIV is unknown. The appli-
cation of 15 cmH2O pressure support during wake in pa-
tients with severe COPD and compensated ventilatory
failure has been shown to cause a 20e50% rise in minute
ventilation, reductions in PaCO2 [12] and significantly
reduced work of breathing [7]. Each patient allocated to
va-NIV was given a one hour trial of pressure support
ventilation at 15 cmH2O whilst awake. During this hour the
minute ventilation and respiratory rate were recorded by
the va-NIV device. The mean value of minute ventilation
was set as the TgMV and the mean value of respiratory rate
set as the ventilators back up respiratory rate. Va-NIV then
attempted to reproduce TgMV overnight by automatically
adjusting the inspiratory pressures in the range 7e25
cmH2O. The expiratory pressure was set at 4 cmH2O.
Ventilator triggers and cycling parameters were adjusted to
patient tolerance.
Outcomes
The primary outcomes were efficacy of ventilation, as
assessed by diurnal arterial blood gases (ABGs) and mean
nocturnal oxygenation (mSpO2), and compliance with
1510 N.S. Oscroft et al.domiciliary NIV as measured by the ventilators. Pulse ox-
imetry (3900 Datex-Ohmeda, Hatfield, UK) was recorded
overnight typically between 2300 and 0700 h and the data
stored and mSpO2 calculated by an automated system
(Download 2000, Stowood Scientific instruments, Oxford,
UK). ABGs were measured either on air or additional oxygen
depending on the patients’ usual therapy and analysed by a
point of care automated blood gas analyser (GEM Premier
3000, Instrumentation Laboratory, Lexington, USA). Sec-
ondary outcomes included: Epworth sleepiness score (ESS),
Medical Research Council (MRC) dyspnoea scale, health-
related quality of life assessed by the St George’s Respira-
tory Questionnaire (SGRQ) [13] and Short Form 36 (SF-36)
[14]; pulmonary function testing; exercise capacity (incre-
mental shuttle walk test) [15] and mean nocturnal PtcCO2
(TCM3 Radiometer, Copenhagen, Denmark, mean calcu-
lated by automated system). The number of days spent as
an inpatient to commence treatment was documented.
Protocol
Patients who gave consent had baseline overnight assess-
ment including continuous PtcCO2 and pulse oximetry.
Respiratory plethysmography with nasal flow measurement
via an integrated system, (Embla, Ontario, Canada) was
performed to screen for obstructive sleep apnoea. Pulmo-
nary function testing, arterial blood gases and chest
radiograph were undertaken. Clinical assessment and
optimisation of medical management were completed by
the physicians of the RSSC and patients meeting trial
criteria were randomised 1:1 to receive va-NIV or pp-NIV.
Patients and carers were trained in the use of NIV and
discharged home once established on treatment. A 24 h
helpline was available to support patients with issues
regarding NIV on discharge. Follow-up occurred at three
months when outcome measures including overnight
attended pulse oximetry and PtcCO2 during NIV were
repeated.
Statistics
Data were analysed to establish normal distribution using
the KolmogoroveSmirnov test. Parametric data were
compared using independent or paired t tests; otherwise
appropriate non-parametric equivalents were used. For all
analyses a p value of <0.05 was considered statistically
significant. Data were analysed using SPSS 20 (Chicago, IL,
USA). The trial was powered (nZ 40), assuming a 20% drop
out rate and standard deviation of 0.5 kPa, to detect a
difference of 0.5 kPa in diurnal PaCO2 between the two
treatment arms. Results are displayed as mean (standard
deviation) unless otherwise specified.
Results
Subjects were recruited between September 2007 and
December 2011. Forty patients met the eligibility criteria
and were randomised, 20 to the pp-NIV group and 20 to the
va-NIV group. Fig. 1 displays the progress of participants
through the trial. Forty-eight percent of patients were male
with a mean age of 68 (8) years and BMI 28 (7) kg/m2. Thepatients had severe COPD with a mean FEV1 0.64 (0.24) L,
28 (10) % predicted and ventilatory failure with a mean
PaCO2 8.0 (0.9) kPa. There were no significant differences
between the groups in terms of mean baseline de-
mographics (Table 1). Eleven of those in the va-NIV group
and twelve in the pp-NIV were transferred following hos-
pital admission with an exacerbation of COPD and the
remainder were admitted electively from home. There
were no statistically significant differences in baseline
characteristics between those who completed the trial and
those who did not.
Non-invasive ventilation titration
It took 3.3 (1.6) days to initiate va-NIV and 5.2 (2.8) days
(p Z 0.02) to start pp-NIV. Va-NIV was provided with a
median (IQR) target minute ventilation of 8.4 (5.7e9.8) L/
min, expiratory pressure of 4 (4-4) cmH2O and backup
respiratory rate of 15 (13.3e19.4) breaths per minute.
Seventeen patients used a full face mask in the pp-NIV
group and 14 in the va-NIV group with the remainder
using nasal masks. Pp-NIV was provided with a median (IQR)
inspiratory pressure of 28 (27.3e30) cmH2O, expiratory
pressure of 5 (5-5) cmH2O and backup respiratory rate of 15
(15-15) breaths per minute.
Comparison between va-NIV and pp-NIV following
domiciliary use
There were no significant differences between the groups
in terms of daytime arterial blood gas measurements,
nocturnal oxygenation or compliance at three months
follow-up (Table 2). There were no significant differences
between groups in the secondary outcomes of health
related quality of life assessment, ESS, MRC Dyspnoea
Scale, pulmonary function testing, exercise tolerance or
mean nocturnal PtcCO2 at three months.
Outcomes following 3 months of NIV
One patient in the va-NIV group and two in the pp-NIV group
died prior to three month follow-up. Both groups showed
significant improvements in daytime PaCO2 and mean
nocturnal SpO2 in comparison to baseline (Table 3). Signif-
icant improvements in daytime PaCO2 and mean nocturnal
SpO2 were seen when comparing baseline and following
three months of therapy in both those started on NIV
following an exacerbation (n Z 19 PaCO2 8.3 (1.1) vs 7.2
(0.7) kPa pZ 0.001, mSpO2 85.5 (5) vs 90.4 (4)% pZ 0.002)
and those started electively on treatment (n Z 15 PaCO2
7.7(0.7) vs 6.7(1)kPa p Z 0.01, mSpO2 84.5(6) vs 88.9(4)%
p Z 0.01). There were significant improvements in both
MRC dyspnoea scale and health-related quality of life
measures (total SGRQ and SF-36 emotional summary score)
(Table 4) in the va-NIV group.
Discussion
This randomised controlled parallel group trial comparing
va-NIV and pp-NIV in the treatment of compensated
Randomized 
(n = 40)
Allocated to pp-NIV
(n = 20)
Received allocated 
intervention (n = 20)
Did not receive allocated 
intervention (n = 0)
A
llo
ca
tio
n
Allocated to va-NIV
(n = 20)
Received allocated 
intervention (n = 18)
Did not receive allocated 
intervention (n = 2,
non-compliance with NIV)
3 
m
on
th
 
fo
llo
w
 u
p Completed (n = 17)
Lost to follow up (n = 1)
Died (n = 2)
Completed (n=17)
Lost to follow up (n = 2)
Died (n = 1)
Analysed (n = 17)
Excluded from analysis
(n = 3)
Analysed (n = 17)
Excluded from analysis
(n = 3)A
na
ly
si
s 
Figure 1 Consort diagram.
Va-NIV versus pp-NIV for ventilatory failure in COPD 1511ventilatory failure associated with COPD demonstrates no
significant differences in daytime arterial blood gases,
nocturnal oxygenation or compliance between the two
modes of ventilation after three months of therapy. Simi-
larly secondary outcomes including health-related quality
of life assessments, pulmonary function testing and exer-
cise capacity did not differ between groups. Although there
were no differences between modes of ventilation the re-
sults support the findings of other studies showing benefit
from the initiation of NIV in hypercapnic COPD patients,
with improvements in diurnal PaCO2 and indices of
nocturnal ventilation [5,16] after three months of treat-
ment in both groups. In addition those in the va-NIV group
reported improvements in the MRC dyspnoea scale, total
SGRQ score and SF-36 emotional summary score in this
unblinded study.
The findings of this study are broadly similar to the re-
sults of previous investigations into the use of va-NIV.
Different va-NIV devices have been compared with pp-NIV
in subjects with COPD [10,17], obesity hypoventilation
syndrome [9,18,19] and neuromuscular and chest wall dis-
orders [20,21]. In COPD patients we did not find a signifi-
cant difference in mean nocturnal PtcCO2 with va-NIV in
comparison to pp-NIV which other investigators have seen
in patients with obesity hypoventilation syndrome [9,19]. In
keeping with the previous studies no other differences in
clinically relevant outcomes between va-NIV and pp-NIV
were found. Comparisons between more traditional vol-
ume preset and pressure preset modes of non-invasive
ventilation have also not reported significant differences
in arterial blood gases, lung function or sleep quality
[22,23]. Pressure preset modes are used more frequently in
practice. [24] This probably reflects the superior leakcompensation of pp-NIV and the availability of inexpensive,
portable ventilators. Laboratory based studies have shown
considerable variation in the performance of different
positive pressure ventilators in terms of leak compensation,
delivery of tidal volume and preset pressures which are not
always predictable from the ventilators’ operating princi-
ples [25e27]. However, the importance of these factors
in vivo is unclear with little effect documented on clinical
parameters [28e30]. The evidence shows there is little
difference in clinical outcomes when comparing different
modes or ventilators used for domiciliary non-invasive
ventilation despite theoretical and demonstrable differ-
ences in performance. However, in clinical practice indi-
vidual patients’ characteristics and their responses to
alternative modes of ventilation differ [31]. This should be
born in mind with the advent of new modes of ventilation
providing alternatives for those who fail standard therapy.
Pressure support levels are positively correlated with
minute ventilation during pp-NIV in stable COPD patients
[7] and the degree of improvement in daytime PaCO2 has
been correlated with the improvement in mean overnight
PaCO2 [6]. Most randomised trials assessing the effects of
NIV in CVF associated with COPD have employed relatively
modest pressure support levels and have not adequately
confirmed increased ventilation during treatment [32].
There is evidence that high intensity NIV (a combination of
high inspiratory pressures and back-up respiratory rates to
provide pressure controlled ventilation) can improve
ventilation sufficiently to impact on diurnal blood gas
measurements and other outcomes in COPD patients with
compensated ventilatory failure [5]. A comparison of high
pressure (low back up rate) and high intensity NIV in CVF in
COPD suggests that it is the high ventilatory pressures that
Table 1 Baseline characteristics of va-NIV and pp-NIV groups.
All pts (n Z 40) va-NIV (n Z 20) pp-NIV (n Z 20) P value*
Age (years) 67.5 (7.9) 67.6 (7.9) 67.4 (8.2) 0.94
Male, no (%) 19 (48) 9 (45) 10 (50) 0.75
BMI (kg/m2) 27.5 (7.2) 25.9 (7.5) 29.0 (6.7) 0.17
Mean nocturnal SpO2 % 85.1 (5.1) 86.0 (5.7) 84.3 (4.5) 0.31
Mean nocturnal PtcCO2 (kPa) 7.1 (2.7) 7.7 (2.9) 6.5 (2.4) 0.18
PaO2 (kPa) 7.11 (1.1) 7.06 (1.0) 7.16 (1.1) 0.77
PaCO2 (kPa) 8.02 (0.9) 7.84 (0.8) 8.20 (1.1) 0.24
LTOT, no (%) 23 (58) 11 (55) 12 (60) 0.94
FEV1(l) 0.64 (0.24) 0.68 (0.25) 0.60 (0.23) 0.33
FEV1% predicted 27.9 (10) 29.4 (11) 26.4 (9.6) 0.39
FEV1/FVC ratio (FER) % 32.1 (11) 32.4 (12) 31.9 (11) 0.90
Exercise tolerance SWT(m) 108.0 (80) 115.4 (98) 102.4 (66) 0.67
ESS 9.3 (5.3) 8.8 (5.5) 9.8 (5.2) 0.60
MRC dyspnoea scale 4.2 (1.0) 4.3 (0.9) 4.1 (1.2) 0.60
SGRQ 67.8 (14) 66.2 (17) 69.3 (10) 0.52
SF-36 physical 30.1 (15) 29.7 (18) 30.4 (13) 0.89
SF-36 emotional 41.4 (19) 41.7 (22) 41.2 (16) 0.93
Length of stay (days) 4.2 (2.4) 3.3 (1.6) 5.2 (2.8) 0.02
All values are presented as Mean (SD) unless stated otherwise. *P value represents differences between va-NIV and pp-NIV. BMI, Body
Mass Index; SpO2, oxygen saturation; PaO2,arterial oxygen tensions, PtcCO2 transcutaneous carbon dioxide, PaCO2, arterial carbon di-
oxide tensions, FEV1, forced expiratory volume in 1 s; (F)VC, (forced) vital capacity; FER, Forced Expiratory Ratio,SWT, Shuttle Walk
Test; ESS, Epworth Sleepiness Scale; MRC Medical Research Council; SGRG, St George’s Respiratory Questionnaire; SF-36, Short Form 36.
Table 2 Between group analysis at 3 month follow-up
(n Z 17).
va-NIV pp-NIV P value
Mean nocturnal SpO2 % 89.7 (4.2) 89.8 (3.9) 0.95
Mean nocturnal PtcCO2
(kPa)
5.75 (2.0) 5.54 (1.6) 0.75
PaO2 (kPa) 8.66 (1.7) 7.88 (1.7) 0.19
PaCO2 (kPa) 6.72 (0.5) 7.25 (1.1) 0.09
LTOT, no (%) 8 (47) 11 (65) 0.30
Compliance (hours) 5.0 (3.1) 4.7 (3.2) 0.80
BMI (kg/m2) 27.0 (7.7) 29.1 (6.9) 0.46
FEV1(l) 0.72 (0.3) 0.68 (0.2) 0.66
FEV1% predicted 32 (12) 28 (8) 0.27
TLC (l) 7.34 (2.2) 5.72 (2.1) 0.12
Exercise tolerance
SWT(m)
129 (90) 133 (71) 0.91
ESS 6.2 (4.1) 8.9 (6.5) 0.18
MRC dyspnoea scale 3.1 (1.4) 3.8 (1.5) 0.23
SGRQ symptomsa 69.6 (23.8) 73.4 (28.3) 0.63
SGRQ activitya 77.0 (20.2) 81.9 (16.1) 0.47
SGRQ impactsa 46.5 (23.3) 51.6 (18.8) 0.51
SGRQ total scorea 59.7 (20.8) 64.4 (15.1) 0.48
SF-36 physicalb 34.1 (23.9) 35.7 (18.8) 0.83
SF-36 emotionalb 56.7 (25.2) 50.4 (19.5) 0.43
Complete case analysis only. All values are presented as Mean
(SD) unless stated otherwise.
a Scores range from 0 to 100, with higher scores indicating
more limitations.
b Scores range from 0 to 100 with higher scores indicating good
health status. N Z 16 for SF-36 and SGRQ data.
1512 N.S. Oscroft et al.are more important [33]. In this study pp-NIV was delivered
at high pressures (median inspiratory pressure 28 cmH2O)
and improvements in physiological outcomes were
apparent after three months of treatment, both in those
started on NIV following an exacerbation and those starting
treatment electively.
The optimum method for setting TgMV for va-NIV is not
known. In this study the va-NIV TgMV and back up respira-
tory rate were set by recording the patients’ respiration
while receiving 15 cmH2O pressure support ventilation for
one hour at rest during wakefulness. The va-NIV device
recorded and calculated the mean values required for TgMV
and back-up respiratory rate making this a simple way of
selecting ventilatory parameters without requiring calcu-
lations or adjustments by medical staff. This provided a
median value for TgMV of 8.4 L and va-NIV delivered similar
physiological outcomes to high pressure pp-NIV. Modes of
ventilation that target minute ventilation have been shown
to increase work of breathing in intubated patients when
patients’ ventilatory demand rises by decreasing pressure
support [34]. No adverse effects from va-NIV were noted
during the course of this study and the compliance (5.0 vs
4.7 h/day) and drop-out rates (15%) were similar between
modes of ventilation.
The initiation of pp-NIV at higher inspiratory pressures
has been reported to require a significantly longer hospital
stay than low pressure NIV [5,35]. Inspiratory pressures are
usually titrated manually in specialist centres during
nocturnal respiratory monitoring, in order to optimise
ventilation. Although not a specific outcome of this trial the
initiation of va-NIV was associated with a significantly
shorter hospital stay. If these results are reproducible in
blinded studies then va-NIV may have a role in reducing
lengths of stay and the requirement for complex overnight
monitoring to initiate NIV effectively.
Table 3 Within group analysis at baseline and 3 month follow-up (n Z 17).
va-NIV pp-NIV
Baseline 3 mths P value Baseline 3 mths P value
Mean nocturnal SpO2 % 85.7 (5.8) 89.7 (4.2) 0.02 84.4 (4.7) 89.8 (3.9) 0.00
Mean nocturnal PtcCO2 (kPa) 8.01 (2.9) 5.75 (2.0) 0.03 6.7 (3.3) 5.5 (1.6) 0.75
PaO2 (kPa) 6.93 (1.0) 8.66 (1.7) 0.00 7.20 (1.2) 7.88 (1.7) 0.12
PaCO2 (kPa) 7.80 (0.8) 6.72 (0.5) 0.00 8.24 (1.1) 7.25 (1.1) 0.01
BMI (kg/m2) 27.5 (7.5) 27.0 (7.7) 0.25 29.5 (7.1) 29.1 (6.9) 0.34
FEV1(l) 0.69 (0.3) 0.72 (0.3) 0.39 0.67 (0.3) 0.68 (0.2) 0.90
FEV1% predicted 30 (12) 32 (12) 0.06 28 (11) 28 (8) 0.91
FEV1/FVC ratio (FER) % 33(12) 33 (12) 0.89 31 (10) 33 (12) 0.37
TLC measured 7.11 (2.07) 7.34 (2.22) 0.37 6.45 (2.38) 5.99 (2.14) 0.04
Exercise tolerance SWT(m) 115 (107) 141 (93) 0.08 107 (82) 111 (58) 0.68
ESS 8.9 (5.4) 6.2 (4.1) 0.08 10.6 (5.4) 8.9 (6.5) 0.35
MRC dyspnoea scale 4.3 (0.9) 3.1 (1.4) 0.01 4.0 (1.3) 3.8 (1.5) 0.29
Complete case analysis only. All values are presented as Mean (SD) unless stated otherwise. 1 Scores range from 0 to 100, with higher
scores indicating more limitations, 2 Scores range from 0 to 100 with higher scores indicating good health status.
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Patients and researchers were not blinded to the inter-
vention provided and this may have introduced bias
although the primary outcomes measured were objective.
Different ventilators were used to provide the ventilatory
modes under investigation. Non-invasive ventilators have
been shown to vary in their performance characteristics in
bench tests [25]. However in clinical trials few differences
in outcomes have been noted [28]. Although naı¨ve to
domiciliary NIV many subjects had experience of acute NIV
and this may have selected those referred for assessment
for domiciliary NIV. No control group without NIV was used
to assess if the improvements with NIV were due to re-
covery following an exacerbation or other confounding
factors. We did not use a strict protocol for initiation of pp-
NIV but the aim of therapy was to maximise ventilation and
this was reflected in the pp-NIV settings reported.
The health related quality of life assessments used in
this study included one generic (SF-36) and one COPD spe-
cific (SGRQ) questionnaire. Statistically and clinically
meaningful changes, meeting the minimum clinically
important difference of 4 points for the SGRQ, were seen in
the va-NIV group in this unblinded study. The SGRQ values
also showed improvement by 4 points in the pp-NIV group
but this did not reach statistical significance. NoTable 4 Within group analysis at baseline and 3 month follow-u
va-NIV
Baseline 3 mths P
SGRQ symptomsa 76.9 (15.5) 69.6 (23.8) 0
SGRQ activitya 86.4 (11.2) 77.0 (20.2) 0
SGRQ impactsa 54.2 (22.6) 46.5 (23.3) 0
SGRQ total scorea 67.6 (16.6) 59.7 (20.8) 0
SF-36 physicalb 28.4 (18.3) 34.1 (23.9) 0
SF-36 emotionalb 39.7 (22.7) 56.7 (25.2) 0
Complete case analysis only. All values are presented as Mean (SD) u
a Scores range from 0 to 100, with higher scores indicating more lim
b Scores range from 0 to 100 with higher scores indicating good headifferences between groups were observed. Since the
design of this study’s protocol better tools for assessing
health related quality of life in chronic respiratory failure
requiring long-term NIV, such as the Severe Respiratory
Insufficiency Questionnaire, have been validated and may
prove more sensitive in measuring responses to treatment
in this population [36].
The duration of follow-up of the study was short and the
outcomes assessed were predominantly physiological. It is
not clear if such physiological measures are good predictors
of clinical outcome in the population studied. The possi-
bility of a difference between modes in clinical outcomes
such as exacerbation rates, hospital admissions and mor-
tality was not evaluated. The primary outcomes of the trial,
mean nocturnal oxygenation and diurnal blood gases, may
have been influenced by two factors: non-invasive venti-
lation and supplemental oxygen. Supplemental oxygen
provision and flow rates were adjusted during the course of
investigation to maintain safe oxygen levels and prevent
excessive CO2 retention. This lowers the value of PaO2 as an
outcome measure and may have affected results indepen-
dently of the NIV mode under investigation. We did not use
mean nocturnal PtcCO2 as a primary outcome measure as
previous clinical experience and experimental data [37]
have shown PtcCO2 may not accurately reflect PaCO2 at
levels greater than 7.3 kPa such as the PaCO2 values of thep (N Z 16).
pp-NIV
value Baseline 3 mths P value
.14 75.3 (14.3) 73.4 (18.3) 0.69
.02 82.5 (13.4) 81.9 (16.1) 0.87
.03 58.6 (12.7) 51.6 (18.8) 0.08
.01 68.6 (10.4) 64.4 (15.1) 0.19
.19 31.5 (9.0) 35.7 (18.8) 0.39
.00 43.8 (13.2) 50.4 (19.5) 0.17
nless stated otherwise.
itations.
lth status.
1514 N.S. Oscroft et al.patients involved in this study. NIV is operator dependant
and many factors may influence outcomes aside from the
ventilator, mode and NIV settings selected. Experienced
providers of NIV are more likely to correctly fit masks,
minimise mask leak and provide appropriate training and
follow-up of those receiving NIV. Therefore the results may
not be generalisable to clinical settings lacking this
expertise.
In summary the initiation of NIV in this population was
associated with improvements in physiological outcomes
with a reduction in hypercapnia and improved oxygenation
overnight. No differences in outcome were found between
pp-NIV and va-NIV following three months of therapy. Both
were well tolerated. Va-NIV was associated with a shorter
hospital stay to initiate therapy in this unblinded study.
This evidence supports the use of NIV in patients with COPD
and compensated ventilatory failure. Volume assured NIV
offers an alternative means of delivering this therapy with
similar physiological outcomes to pressure preset NIV.
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